Efficacy and safety of abbv-599 high dose (elsubrutinib 60 mg and upadacitinib 30 mg) and upadacitinib monotherapy for the treatment of systemic lupus erythematosus: a phase 2, double-blind, placebo-controlled trial

J. T. Merrill, Y. Tanaka, D. D'cruz, K. Vila, D. Siri, X. Zeng, K. D'silva, L. Cheng, T. Sornasse, T. Doan, D. Kruzikas, A. Friedman

ANNALS OF THE RHEUMATIC DISEASES（2023）

引用 0|浏览0